Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128171	Articles
104822	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 03/31/2025 at 14:00, 10 months 7 days ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Jaguar Health, Inc. reports a 20% increase in total net revenue for 2024, reaching $11.7 million. Expecting first results in Q2 2025 for crofelemer trials. FDA meeting scheduled for Phase 3 OnTarget trial

Financial Results Jaguar Health Net Revenue FDA Meeting POC Trials
BRIEF

published on 03/28/2025 at 14:05, 10 months 10 days ago

Jaguar Health Highlights Veterinary Support for Canalevia-CA1

FDA Approval Canalevia-CA1 Veterinary Oncology Dog Chemotherapy Non-Antimicrobial Treatment
BRIEF

published on 03/28/2025 at 14:05, 10 months 10 days ago

Jaguar Health souligne son soutien vétérinaire à Canalevia-CA1

Canalevia-CA1 Approbation De La FDA Oncologie Vétérinaire Chimiothérapie Canine Traitement Non Antimicrobien
PRESS RELEASE

published on 03/28/2025 at 14:00, 10 months 10 days ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Jaguar Health's Canalevia-CA1 receives FDA approval for chemotherapy-induced diarrhea in dogs, addressing a critical unmet need in veterinary oncology

FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea Veterinary Oncology
BRIEF

published on 03/27/2025 at 13:35, 10 months 11 days ago

Jaguar Health Secures FDA Meeting to Discuss Crofelemer Results in Breast Cancer Trial

Crofelemer Jaguar Health Breast Cancer FDA Meeting OnTarget Study
BRIEF

published on 03/27/2025 at 13:35, 10 months 11 days ago

Jaguar Health obtient une réunion avec la FDA pour discuter des résultats de l'essai Crofelemer sur le cancer du sein

Crofelemer Jaguar Health Cancer Du Sein Réunion De La FDA Étude OnTarget
PRESS RELEASE

published on 03/27/2025 at 13:30, 10 months 11 days ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Napo Pharmaceuticals presents statistically significant responder analysis results for crofelemer in breast cancer patients at San Antonio Breast Cancer Symposium and MASCC, FDA Type C Meeting scheduled for 2025

Napo Pharmaceuticals Crofelemer Breast Cancer FDA Meeting Responder Analysis
BRIEF

published on 03/26/2025 at 16:05, 10 months 12 days ago

Jaguar Health participera à la conférence Emerging Growth et organisera un webcast pour les investisseurs.

Jaguar Health Conférence Sur La Croissance Émergente Webcast Pour Les Investisseurs Développement Crofelemer Résultats Financiers Du Quatrième Trimestre 2024
BRIEF

published on 03/26/2025 at 16:05, 10 months 12 days ago

Jaguar Health to Present at Emerging Growth Conference and Host Investor Webcast

Investor Webcast Jaguar Health Emerging Growth Conference Crofelemer Development Q4 2024 Financials
PRESS RELEASE

published on 03/26/2025 at 16:00, 10 months 12 days ago

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
Jaguar Health, Inc. announces virtual presentation and investor webcast dates. Company to file annual report on March 31, 2025. Lisa Conte to discuss upcoming developments

Virtual Presentation Investor Webcast Annual Report Lisa Conte Jaguar Health Inc.

Accesswire

Published on 02/07/2026 at 01:00, 1 day 6 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 8 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 9 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 16 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 18 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 10 hours 58 minutes ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 15 hours 23 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 15 hours 38 minutes ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 12 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 14 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 1 day 13 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 1 day 13 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 15 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 15 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE